TSTorbjörn Schultz

Torbjörn Schultz

*This is an algorithmically generated author record based on publicly available information.

Torbjörn Schultz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Economic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis

    by Giovanni Galvis Rojas, Peter Strang, Torbjörn Schultz, Lars-Åke Levin

    Background and purpose: End-of-life healthcare costs in advanced breast cancer (ABC) are substantial, yet the contribution of acute, life-threatening complications, hospital-requiring infections and venous thromboembolism (VTE), remains uncharacterised. We quantified adjusted complication-specific costs. Patient/material and methods: Population-based cohort study of 1,363 women who died with ABC in the Stockholm Region (2015–2023). Healthcare costs during the last 12 months of life were estimated using the Region Stockholm simulated cost (SIM) model and stratified by complication status, age group, and Hospital Frailty Risk Score (HFRS). Generalised linear models estimated the independent associations between hospital-requiring infections, VTE and total costs, adjusting sequentially for age, frailty risk, and systemic therapy. Results: Overall mean costs were 597 thousand SEK (tSEK; 95% CI: 578–616). Hospital-requiring infections occurred in 18% of patients and were independently associated with 29% higher costs after full adjustment (cost ratio 1.29, 95% confidence interval [CI]: 1.20–1.39). VTE occurred in 8% of patients, of whom 80% had pulmonary embolism; it was associated with higher costs unadjusted (1.16, p = 0.010) but not after adjustment for frailty risk (1.08, 95% CI: 0.97–1.21). Concomitant VTE (27 patients, 11% of those infected) gave costs similar to infection alone. High frailty risk showed the strongest independent association with cost in the infection model (cost ratio 1.54, 95% CI: 1.34–1.78). Interpretation: Hospital-requiring infections were independently associated with higher end-of-life costs in ABC; VTE was not, once frailty risk was adjusted for. These findings add a complication-specific dimension to frailty-based risk stratification and support targeted prevention in end-of-life care.

  • Open Access

    End-of-life dementia: demographic, clinical as well as direct health care cost differences in nursing homes vs. ordinary housing

    by Peter Strang, Dag Salaj, Torbjörn Schultz

    Background: In late stages, dementia is a palliative diagnosis and the majority of those affected are cared for in nursing homes, but some manage in ordinary housing. The aim was to study how these two groups differ as regards clinical characteristics, healthcare utilization and costs. Methods: A registry study (Region Stockholm) was performed on deceased patients (≥ 18 years) with a dementia diagnosis during their last year of life, for the years 2015–2023. Pairwise comparisons between nursing homes and ordinary housing were made and multivariable binary logistic regression models were created. Results: Persons in ordinary housing were significantly younger (84 vs. 86 years old), more often male (51% vs. 39%), they had higher frailty risk scores (Hospital Frailty Risk Scores) and had more often a concomitant metastatic cancer (9% vs. 2%), p < 0.0001 in all comparisons. To meet the care needs, these persons received more often specialized palliative care, they had a higher use of geriatric services, they had more emergency room visits and died more often in emergency hospitals, p < 0.0001 in all comparisons. In contrast, those who were referred to nursing homes were more often women, older, they had more often Alzheimer´s disease (compared to other dementias), p < 0.0001 in all comparisons. As regards medical utilization, the associated costs were equally distributed between women and men in ordinary housing, whereas the costs were significantly higher for men compared with women in nursing homes. Conclusions: Persons with late-stage dementia in ordinary housing are more often younger, men and they have more often comorbidities, including cancer. They have significantly higher health care utilization, and the costs are equally distributed between women and men.

  • Open Access

    Healthcare costs and resource use in advanced breast cancer at the end of life: a register study

    by Giovanni Galvis Rojas, Peter Strang, Torbjörn Schultz, Lars-Åke Levin

    Background and purpose: Advanced breast cancer (ABC) involves substantial end-of-life (EOL) healthcare use and costs. Understanding cost drivers can inform care delivery and resource allocation.Patient/material and methods: We conducted a retrospective, population-based study of individuals (n = 1,437) who died with breast cancer in the Stockholm Region (2015–2023). Healthcare utilization and costs during the last 12 months of life were obtained from the Stockholm Regional Healthcare Data Repository (VAL) and estimated using the Region Stockholm cost model. Variables included age, sex, socioeconomic status (Mosaic), Charlson Comorbidity Index, Hospital Frailty Risk Score (HFRS), systemic therapy, and place of death. Descriptive statistics and generalized linear models assessed cost associations.Results: Total costs rose toward EOL, increasing 140% in the final 3 months versus the prior quarter. Hospitalizations and specialized palliative care drove costs, while outpatient visits declined. Younger age (18–69 years), high frailty (HFRS > 15), and systemic therapy were independently associated with higher costs. Hospital death was associated with lower expenditures than dying elsewhere (rate ratio [RR]: 0.84, 95% confidence interval [CI]: 0.78–0.91). The top 5% of cost users were mainly younger, frail patients receiving systemic therapy.Interpretation: ABC-related costs escalate in the final year of life, driven by hospitalizations, palliative care, and systemic therapies. Younger, frailer patients incur higher costs, while those dying in hospital settings are associated with lower costs. Early palliative integration and frailty-based risk stratification were associated with distinct patterns of healthcare utilization and costs toward the EOL.


  • Open Access

    Clinical Depression in the Last Year in Life in Persons Dying from Non-Cancer Conditions—Real World Data

    by Peter Strang, Anette Alvariza, Torbjörn Schultz, Linda Björkhem-Bergman

    Background/Objectives: Published prevalences of depression are mainly based on measurements of depressive symptoms, whereas data on clinical depressions are lacking. Our aim was to map the prevalence of ICD-10 diagnoses of depression made by physicians in routine healthcare, during the last year of life in non-cancer conditions and to study associations with clinical variables. Methods: A registry study on all persons in ordinary accommodation, dying in 2015–2023 in non-cancer conditions. Results: Of 62,228 persons dying from non-cancer conditions, 4391 (7.1%) were formally diagnosed with depression during the last year in life. Depression was significantly more common in women than in men, 8.0% vs. 6.3% (p < 0.001); adjusted odds ratio (aOR) 1.46 (95%CI 1.37–1.55). Prevalence of depression was highest in persons 18–44 years (18.3%) and lowest in persons >85 years old (5.7%) (p < 0.001); aOR 4.12 (95%CI 3.66–4.63). It was also more common in persons living in more affluent areas, aOR 1.19 (95%CI 1.10–1.29). The condition was most frequent in persons with Parkinson’s disease (9.4%) and COPD (8.2%). Depression was associated with more emergency room visits, 89.5% vs. 81.3% (p < 0.001), and visits in psychiatric services in the last year in life, 41.4% vs. 8.8% (p < 0.001). Depression was less prevalent in persons admitted to palliative care (p = 0.007). Conclusions: The highest frequencies were found in women, younger persons, and those living in affluent areas, but also in certain diagnoses such as Parkinson’s disease and COPD. Clinical depression in the last year of life is associated with more emergency room visits and utilization of psychiatric services.


  • Open Access

    High Frequency of Depression in Advanced Cancer with Concomitant Comorbidities: A Registry Study

    by Peter Strang, Torbjörn Schultz

    Background/objectives: Depression is a common complication of cancer and is associated with distress and reduced participation in medical care. The prevalence is still uncertain in advanced cancer due to methodological problems. Our aim was to study depression in the last year of life and related variables. Methods: We used an administrative database and analyzed clinically verified diagnoses of depression during the last year of life for 27,343 persons (nursing home residents excluded) and related the data to age, sex, socioeconomic status on an area level (Mosaic system), and frailty risk as calculated by the Hospital Frailty Risk Score (HFRS). T-tests, chi-2 tests, and binary logistic regression models were used. Results: During the last year of life, a clinical diagnosis of depression was found in 1168/27,343 (4.3%) cases and more frequently seen in women (4.8% vs. 3.8%, p = 0.001), in the elderly aged 80 years or more, p = 0.03, and especially in persons with a frailty risk according to the HFRS, with rates of 3.3%, 5.3% and 7.8% in the low-risk, intermediate and high-risk groups, respectively (p < 0.001), whereas no differences were found based on socioeconomic status. In a multiple logistic regression model, being female (aOR 1.30, 95% CI 1.16–1.46) or having an intermediate (1.66, 1.46–1.88) or high frailty risk (2.57, 2.10–3.14) retained the predictive value (p < 0.001, respectively). Conclusions: Depression is more common in women and, above all, in people with multimorbidity. Depression affects the amount of health care needed, including the need for psychiatric care. Therefore, it should be included in clinical decision-making, especially as depression is associated with poorer prognosis in cancer.


  • Open Access

    High Rate of Thromboembolic Events in the Last Year of Life of Cancer Patients: A Registry Study

    by Peter Strang, Torbjörn Schultz

    Background/Objectives: Venous thromboembolism (VTE) is associated with cancer, but we wanted to show VTE data for the last year of life, adjusting for age, sex, socioeconomic status and comorbidities. We also wanted to study the possible increase in VTE month by month, as well as time trends from 2015 to 2023. Methods: A cohort of 27,423 deceased people with cancer were analyzed with t-tests, chi-square tests and binary logistic regression models. Results: In total, 13.6% had at least one VTE episode during the last year of life and the VTE rate increased month by month (p < 0.0001). In adjusted models, higher VTE rates were associated with younger age and being a woman (p < 0.0001), both for all VTE as well as separately for pulmonary embolism (PE). The VTE rate increased by 47% from 11.1% in 2015 to 16.3% in 2023, and with significant differences for the pre-COVID-19 and COVID-19 years (i.e., 2015–2019 compared to 2020–2023, p < 0.0001). Conclusions: VTE is common in the last year of life and increases month by month. Higher frequencies are associated with female sex but especially with being younger, or having certain cancer forms such as pancreatic, gynecologic or lung cancer. The rate of VTE increased from 2015 to 2023. This is of interest as VTE has been associated with higher treatment intensity and with poorer prognosis and should be considered in the decision-making process.


  • Ascites as a Predictive Factor in Malignancies in the Last Year of Life–Comparison Between Different Cancer Types

    by Johan Fridegren, Linda Björkhem-Bergman, Torbjörn Schultz, Peter Strang

    Background: Ascites in malignancies is usually associated with poor prognosis, but the predictive value may vary between different cancer types. Objectives: The aim was to map the frequency and temporal pattern of paracentesis in patients with malignancies in relation to time to death and to evaluate the occurrence of ascites as a predictive factor in different cancer types, with a limitation to the last year of life. Design: A retrospective study based on registry data covering all care visits in the Stockholm Region, Sweden, for seven years was performed. All deceased subjects that had at least one registered paracentesis in the last year of life were included. Results: Of 23,056 subjects dying from cancer, 1863 had undergone paracentesis in the last year of life (8.0%). Ascites requiring paracentesis was most frequently seen in appendiceal cancer (38%), ovarian cancer (35%), cholangiocarcinoma (26%), hepatocellular carcinoma (19%), and pancreatic cancer (17%). The median time for the first paracentesis in all cancer types varied between 248 and 20 days before death. For ovarian cancer, the median time for first paracentesis differed significantly compared with upper gastro-intestinal (GI) cancers, 81 days compared with 30 days (p < 0.0001). Ascites in prostate cancer was rare,1.9%, but when present, a pronounced increase in the frequency of paracentesis was observed in the last three months of life. Conclusion: The occurrence of paracentesis in patients with advanced cancer is generally a sign that death is approaching within the coming months, especially in upper GI cancer. For ovarian and appendiceal cancers, ascites is less useful as a predictive tool.


  • Open Access

    Differences in Health Care Expenditures by Cancer Patients During Their Last Year of Life: A Registry-Based Study

    by Peter Strang, Max Petzold, Linda Björkhem-Bergman, Torbjörn Schultz

    Background. During the last year of life, persons with cancer should probably have similar care needs and costs, but studies suggest otherwise. Methods. A study of direct medical costs (excluding costs for expensive prescription drugs) was performed based on registry data in Stockholm County, which covers 2.4 million inhabitants, for all deceased persons with cancer during 2015–2021. The data were mainly analyzed with the aid of multiple regression models, including Generalized Linear Models (GLMs). Results. In a population of 20,431 deceased persons with cancer, the costs increased month by month (p < 0.0001). Higher costs were mainly associated with lower age (p < 0.0001), higher risk of frailty, as measured by the Hospital Frailty Risk Scale (p < 0.0001), and having a hematological malignancy. In a separate model, where those 5% with the highest costs were identified, these variables were strengthened. Sex and socio-economic groups on an area level had little or no significance. Systemic cancer treatments during the last month of life and acute hospitals as place of death had only a moderate impact on costs in adjusted models. Conclusions. Higher costs are mainly related to lower age, higher frailty risk and having a hematological malignancy, and the effects are both statistically and clinically significant despite the fact that expensive drugs were not included. On the other hand, the costs were mainly comparable in regard to sex or socio-economic factors, indicating equal care.


  • Open Access

    Age and co-morbidities as independent risk factors of infections leading to hospital admission in the last year of life among the elderly: A retrospective registry-based study

    by Linda Björkhem-Bergman, Torbjörn Schultz, Peter Strang

    Background: The immune system declines with age, but the impact of chronological age may be affected by sex, co-morbidities, and sociodemographic factors. Objective: The article aims to study infections associated with hospital admission in the elderly in their last year of life and the impact of age, sex, co-morbidities, and sociodemographic factors. Method: A retrospective study based on registry data covering all care visits in Stockholm Region, Sweden, for 7 years was conducted. All deceased subjects with at least one hospital admission with infection as the main diagnosis in the last year of life were compared with subjects with no such admission. Subjects were categorized into three different age-groups 65–79, 80–89, and 90 years and above. Co-morbidity was measured by the Charlson Comorbidity Index (CCI) and sociodemographic factors were assessed using the ‘Mosaic-system’. Subjects living in nursing homes were analyzed separately. Uni- and multivariable logistic regressions were conducted. Results: Of the 55,238 subjects in the study population, 14,192 (26%) had at least one hospital admission due to infection in the last year of life. The risk of having a severe infection increased with age, adjusted odds ratio (OR): 1.30 (1.25–1.36), and 1.60 (1.52–1.69) for the age-groups 80–89 and ≥ 90 compared to the age-group 65–79. The most important factor for infection was a high co-morbidity score; adjusted OR: 1.75 (1.68–1.82). Male sex and living in a less affluent area were weaker risk factors for infections. Conclusion: Chronological age and co-morbidities are independent risk factors of infections associated with hospital admission in the last year in life while male sex and sociodemographic factors have less impact.


  • Open Access

    The Impact of Frailty on Palliative Care Receipt, Emergency Room Visits and Hospital Deaths in Cancer Patients: A Registry-Based Study

    by Peter Strang, Torbjörn Schultz

    Background. Eastern Cooperative Oncology Group (ECOG) performance status is used in decision-making to identify fragile patients, despite the development of new and possibly more reliable measures. This study aimed to examine the impact of frailty on end-of-life healthcare utilization in deceased cancer patients. Method. Hospital Frailty Risk Scores (HFRS) were calculated based on 109 weighted International Classification of Diseases 10th revision (ICD-10) diagnoses, and HFRS was related to (a) receipt of specialized palliative care, (b) unplanned emergency room (ER) visits during the last month of life, and (c) acute hospital deaths. Results. A total of 20,431 deceased cancer patients in ordinary accommodations were studied (nursing home residents were excluded). Frailty, as defined by the HFRS, was more common in men than in women (42% vs. 38%, p < 0.001) and in people residing in less affluent residential areas (42% vs. 39%, p < 0.001). Patients with frailty were older (74.1 years vs. 70.4 years, p < 0.001). They received specialized palliative care (SPC) less often (76% vs. 81%, p < 0.001) but had more unplanned ER visits (50% vs. 35%, p < 0.001), and died more often in acute hospital settings (22% vs. 15%, p < 0.001). In multiple logistic regression models, the odds ratio (OR) was higher for frail people concerning ER visits (OR 1.81 (1.71–1.92), p < 0.001) and hospital deaths (OR 1.66 (1.51–1.81), p < 0.001), also in adjusted models, when controlled for age, sex, socioeconomic status at the area level, and for receipt of SPC. Conclusion. Frailty, as measured by the HFRS, significantly affects end-of-life cancer patients and should be considered in oncologic decision-making.